Editorial: APOE4-associated heterogeneity in the pathogenesis of Alzheimer's disease

Editorial on the Research Topic
APOE4-associated heterogeneity in the pathogenesis of Alzheimer's disease

Possession of the Apolipoprotein E ε4 (APOE4) allele is the major genetic risk factor for the late-onset form of Alzheimer's disease (AD). While substantial research has been devoted to understanding the mechanisms responsible for the elevated AD risk among APOE4 carriers, much less research has focused on the specific pathological differences that exist between APOE4 carriers and non-carriers. This information is crucial, however, as we advance into a new era of AD research and treatment, where understanding these pathological differences may enable clinicians to use targeted strategies for AD prevention, diagnosis, and therapy in APOE4 carriers vs. non-carriers.

To help elucidate this APOE4-associated heterogeneity in AD pathogenesis, we organized a Research Topic devoted to this subject. As described below, the seven articles that were published as part of this Research Topic each help elucidate an important factor related to this APOE4-associated heterogeneity. Importantly, these articles also highlight the diverse effects that an individual's APOE genotype has on their body and brain during aging and AD pathogenesis.

The primary role of the apoE protein is to aid in the transport and cellular uptake of cholesterol and other lipids within the periphery and the CNS (Yamazaki et al., 2019). Mares et al. utilized human lipidomics and transcriptomics databases from brain tissues and blood samples from the ROSMAP cohort. The authors identified a convergence of differences between cognitively unimpaired APOE4 carriers and MCI patients, especially in lipids associated with the acyl chain remodeling pathway. This connection implies that membrane composition and lipid signaling related to this pathway are altered early in the process of AD pathogenesis in APOE4 carriers, occurring even before any clinical symptoms are observed.

ApoE-containing lipoproteins that circulate through the blood are primarily produced by the liver, while those that exist in the brain are primarily produced by astrocytes. While these two apoE lipoprotein pools are physically separated from one another by the blood brain barrier, Han et al. found that liver function in APOE4 carriers can have a significant impact on the development of AD-related brain pathology. Using two independent cohorts (ADNI and a study at Hallym University Medical Center), the authors reported that liver damage correlated with an increased risk of brain Aβ and AD, but that this connection was unique to APOE4 carriers. Thus, APOE4 genetic risk may combine with liver dysfunction risk to drive AD pathogenesis. Furthermore, Guan et al. assessed the effect of APOE4 carrier status on the interaction between diet, blood biomarkers, and brain white matter integrity in a cohort of 156 individuals of Puerto Rican descent over 12 years. They found that APOE4 carriers possessed greater associations between numerous baseline dietary factors/blood biomarkers and 12-year medial temporal lobe white matter integrity. On the other hand, while cardiovascular disease and body mass index were also associated with white matter integrity, this association was not affected by APOE4 carrier status.

Another important aspect of APOE4-associated AD risk is the varying disease penetrance that exists between male and female APOE4 carriers and between APOE4 carriers with differing races/ethnicities (Belloy et al., 2023; Farrer et al., 1997). For example, it has been reported that female APOE4 carriers (regardless of racial/ethnic background) possess an increased risk of AD compared to their male counterparts (Belloy et al., 2023). While the reason for this increased AD risk in women has not been fully elucidated, previous studies have uncovered specific metabolic changes that occur in the female brain during menopause as a potential mediating factor (Rahman et al., 2020; Breeze et al., 2024), with several studies reporting that early intervention with hormone replacement therapy can reduce AD risk in women (Nerattini et al., 2023; Coughlan et al., 2023; Saleh et al., 2023). On this topic, Wugalter et al. measured serum estrone (E1) and estradiol (E2) levels in postmenopausal women from the MsBrain cohort to assess the separate and interactive associations of estrogen, plasma AD biomarkers, and APOE4 carrier status on regional brain volumes. The authors reported that higher endogenous estrogen levels were associated with increased regional brain volumes only in women with more severe AD biomarker profiles. However, this effect was driven by APOE4 non-carriers, suggesting that APOE4 carriers do not benefit similarly from higher estrogen levels on regional brain volumes.

Balu et al. also investigated the interaction of APOE4 carrier status and sex, this time in a mouse model of APOE genotype and AD. Utilizing the EFAD mouse model of AD, the authors reported that the combination of APOE4 and female sex led to earlier cognitive impairment in the mice, as well as increased Aβ pathology and higher levels of neuroinflammation. Interestingly, female APOE3 EFAD mice possessed similar pathology to male APOE4 EFAD mice, indicating that female sex alone can lead to greater AD pathology in these mice. Meanwhile, Christensen et al. utilized only female APOE mice to explore the relationship between obesity (a modifiable AD risk factor), estrogen therapy, and cognitive deficits. When female APOE3/3, APOE3/4, and APOE4/4 mice were fed a high fat diet (HFD), the APOE4/4 mice were overall more impaired cognitively and had worse metabolic function; however, the APOE3/3 mice were more affected by the HFD compared to their regular chow-fed counterparts. Interestingly, estradiol treatment improved metabolic function and cognitive performance in all the HFD-treated mice, but the APOE4/4 mice benefitted the most.

Lastly, it is important to note that APOE4 associated heterogeneity is already contributing to real-world AD treatment decisions, since APOE4 carriers are known to be at greater risk of developing Amyloid-Related Imaging Abnormalities (ARIA) while being treated with the newly approved amyloid immunotherapies Leqembi and Kisunla (Sims et al., 2023; van Dyck et al., 2023). In a review article by Foley and Wilcock, the authors highlighted three hypothesized mechanisms by which APOE4 may be influencing ARIA risk: (1) reduced cerebrovascular integrity, (2) increased neuroinflammation and immune dysregulation, and (3) elevated levels of cerebral amyloid angiopathy (CAA). Importantly, they detail how these three potential mechanisms could be pursued in clinical and preclinical studies, emphasizing that the usefulness of AD therapies, now and in the future, requires that the AD research community understand the pathological heterogeneity mediated by possession of the APOE4 allele.

Author contributions

ET: Writing – original draft, Writing – review & editing. GR: Writing – original draft, Writing – review & editing. TN: Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a grant from the NIA to TN (R01AG070202).

Conflict of interest

TN is a consultant for Mubadala Capital.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Belloy, M. E., Andrews, S. J., Le Guen, Y., Cuccaro, M., Farrer, L. A., Napolioni, V., et al. (2023). APOE genotype and alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 80, 1284–1294. doi: 10.1001/jamaneurol.2023.3599

PubMed Abstract | Crossref Full Text | Google Scholar

Breeze, B., Connell, E., Wileman, T., Muller, M., Vauzour, D., Pontifex, M. G., et al. (2024). Menopause and Alzheimer's disease susceptibility: exploring the potential mechanisms. Brain Res. 1844:149170. doi: 10.1016/j.brainres.2024.149170

PubMed Abstract | Crossref Full Text | Google Scholar

Coughlan, G. T., Betthauser, T. J., Boyle, R., Koscik, R. L., Klinger, H. M., Chibnik, L. B., et al. (2023). Association of age at menopause and hormone therapy use with tau and beta-amyloid positron emission tomography. JAMA Neurol. 80, 462–473. doi: 10.1001/jamaneurol.2023.0455

PubMed Abstract | Crossref Full Text | Google Scholar

Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349–1356. doi: 10.1001/jama.1997.03550160069041

Crossref Full Text | Google Scholar

Nerattini, M., Jett, S., Andy, C., Carlton, C., Zarate, C., Boneu, C., et al. (2023). Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia. Front. Aging Neurosci. 15:1260427. doi: 10.3389/fnagi.2023.1260427

PubMed Abstract | Crossref Full Text | Google Scholar

Rahman, A., Schelbaum, E., Hoffman, K., Diaz, I., Hristov, H., Andrews, R., et al. (2020). Sex-driven modifiers of Alzheimer risk: a multimodality brain imaging study. Neurology 95, e166–e178. doi: 10.1212/WNL.0000000000009781

PubMed Abstract | Crossref Full Text | Google Scholar

Saleh, R. N. M., Hornberger, M., Ritchie, C. W., and Minihane, A. M. (2023). Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort. Alzheimers Res. Ther. 15:10. doi: 10.1186/s13195-022-01121-5

PubMed Abstract | Crossref Full Text | Google Scholar

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., et al. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527. doi: 10.1001/jama.2023.13239

PubMed Abstract | Crossref Full Text | Google Scholar

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2023). Lecanemab in early Alzheimer's disease. N. Engl. J. Med. 388, 9–21. doi: 10.1056/NEJMoa2212948

PubMed Abstract | Crossref Full Text | Google Scholar

Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C., and Bu, G. (2019). Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15, 501–518. doi: 10.1038/s41582-019-0228-7

PubMed Abstract | Crossref Full Text | Google Scholar